Cannabidiol combination compositions

A technology of cannabidiol and composition, which is applied in the field of cannabidiol joint composition, can solve problems such as no improvement, no effective, pain relief or no joint damage

Pending Publication Date: 2021-06-08
COMPANION SCI LLC
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Although these compositions and complexes were found to be safe in numerous human and animal trials, they were not found to be effective and showed little or no improvement in pain relief or joint damage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cannabidiol combination compositions
  • Cannabidiol combination compositions
  • Cannabidiol combination compositions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0091] Example 1 - Permeation

[0092] Three different oral formulations of water soluble CBD were tested, F#01 (20%), L#02 (2.5% CBD) and I#03 (20% CBD), and were administered to rats at 15 mg / Kg.

[0093] Three formulations were tested in combination with 500 mg / Kg glucosamine (Gln).

[0094] The total application amount was 10 mL / Kg (CBD+Gln).

[0095] Tests were performed on Sprague Dawley male rats (n=3 / group).

[0096] A single dose of PO containing CBD and GIn was given at t=0.

[0097] CBD and Gln plasma concentrations were measured 1, 4 and 8 hours after a single administration.

[0098] Eight hours after oral administration, the concentration of Gln in the synovial fluid was measured.

[0099] result:

[0100] Such as figure 1 As shown, no significant difference in Gln plasma concentration was found among the groups.

[0101] One hour after administration, the average Gln plasma concentration was 2.039 ng / mL, which dropped to 134 ng / mL (93.4% lower than the ba...

Embodiment 2

[0108] Example 2 - Dog Treats

[0109] Two compositions comprising CBD and Gln were formulated as dog treats.

[0110] Composition A for small dogs contained 2.5mg CBD and 400mg Gln in a 6g treat.

[0111] Composition A for medium-sized dogs contained 4.5mg CBD and 700mg Gln in a 10g treat.

[0112] Composition A for large dogs contained 7.5mg CBD and 1.2g Gln in a 12g treat.

[0113] Composition B contained 10 mg CBD and 1.5 g Gln.

[0114] Each composition was formulated into a dog treat using soft dog treats and flavorings. Figure 5 It is a photograph of dog snacks.

[0115] Treats were administered to 5 healthy dogs.

[0116] Dogs readily snacked, indicating that the canine treat preparation had a desirable taste, while the bad taste of CBD was masked.

Embodiment 3

[0117] Example 3 - Ratio

[0118] The trial included approximately four animal groups (3 for synovial fluid and 1 for plasma) for four different CBD:Gln ratios (1:5, 1:10, 1:20 and 1:30) , which included two CBD formulations and a control (Gln only). Each of these 48 groups housed 8 rats for a total of 384 animals (128 in plasma vs. 256 in synovial fluid).

[0119] The total dose is 10 mL / Kg.

[0120] Tests were performed on Sprague Dawley male rats (n=3 / group).

[0121] A single dose of PO was given at t=0.

[0122] CBD and Gln plasma concentrations were checked 1, 4 and 8 hours after a single administration.

[0123] Examine synovial fluid 8 hours after oral administration.

[0124] The goal is to optimize the CBD:Gln ratio to achieve maximum Gln concentration in synovial fluid while maintaining acceptable and applicable oral doses of CBD and Gln.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Embodiments of the invention are directed to formulations comprising Cannabidiol (CBD) and glucosamine (Gln). Further embodiments of the invention are directed to methods of treating or preventing Arthritis, Osteoarthritis, Rheumatoid arthritis, Osteoporosis, Osteopenia, jaw pain, joint pain, knee pain, back pain, multiple sclerosis, Osteomalacia and Paget's disease of bone, wherein the method comprises administering a formulation comprising Cannabidiol (CBD) and glucosamine (Gln).

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of U.S. Provisional Application No. 62 / 692,865, filed July 2, 2018, which is hereby incorporated by reference in its entirety. technical field [0003] The present disclosure generally relates to formulations and methods of treatment comprising cannabidiol (CBD) and glucosamine (Gln). Background technique [0004] Osteoarthritis (OA) is the most common form of arthritis, affecting millions of people worldwide. It occurs when the protective cartilage that cushions the ends of bones wears down over time. [0005] Although osteoarthritis can damage any joint, the condition most commonly affects the joints of the hands, knees, hips, and spine. [0006] Osteoarthritis is a common disease in small animals as it exists in humans. It is estimated that approximately 30-50% of all dogs and cats will be affected by osteoarthritis at some point in their lives (according to Willows Veterinary ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7008A61K31/00A61K31/05A61K36/185A61P19/02
CPCA61P19/02A61K31/7008A61K36/185A61K31/05A61K36/324A61K2300/00A61K31/047A61K31/10A61K31/19A61K31/737
Inventor G·瓦克宁T·巴尔
Owner COMPANION SCI LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap